dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Peralta-Garcia, Alejandro |
dc.contributor.author | Torrens-Fontanals, Mariona |
dc.contributor.author | Stepniewski, Tomasz Maciej |
dc.contributor.author | Grau Exposito, Judit |
dc.contributor.author | Perea Pérez, David |
dc.contributor.author | Ayinampudi, Vikram |
dc.contributor.author | Buzón Gómez, María José |
dc.contributor.author | Genesca Ferrer, Meritxell |
dc.date.accessioned | 2022-06-15T11:45:19Z |
dc.date.available | 2022-06-15T11:45:19Z |
dc.date.issued | 2021-12 |
dc.identifier.citation | Peralta-Garcia A, Torrens-Fontanals M, Stepniewski TM, Grau-Expósito J, Perea D, Ayinampudi V, et al. Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells. Int J Mol Sci. 2021 Dec;22(24):13592. |
dc.identifier.issn | 1422-0067 |
dc.identifier.uri | https://hdl.handle.net/11351/7684 |
dc.description | COVID-19; Reutilització de medicaments; Assajos d'entrada de cèl·lules virals |
dc.description.sponsorship | This research was funded by the Spanish Ministry of Science, Innovation, and Universities (FPU16/01209 to M.T.-F.); the Health department of the Government of Catalonia (DGRIS 3_9 to A.P.G. and J.S. and DGRIS 1_5 to M.J.B. and M.G.). |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | International Journal of Molecular Sciences;22(24) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Medicaments antivírics |
dc.subject | COVID-19 (Malaltia) |
dc.subject | Medicaments - Ús |
dc.subject.mesh | Antiviral Agents |
dc.subject.mesh | /pharmacology |
dc.subject.mesh | Drug Repositioning |
dc.subject.mesh | Coronavirus Infections |
dc.title | Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/ijms222413592 |
dc.subject.decs | antivíricos |
dc.subject.decs | /farmacología |
dc.subject.decs | nuevas indicaciones de medicamentos |
dc.subject.decs | infecciones por Coronavirus |
dc.relation.publishversion | https://doi.org/10.3390/ijms222413592 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Peralta-Garcia A, Torrens-Fontanals M] Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Hospital del Mar Medical Research Institute (IMIM), Pompeu Fabra University (UPF), 08003 Barcelona, Spain. [Stepniewski TM] Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Hospital del Mar Medical Research Institute (IMIM), Pompeu Fabra University (UPF), 08003 Barcelona, Spain. InterAx Biotech AG, PARK InnovAARE, 5234 Villigen, Switzerland. [Grau-Expósito J, Perea D, Buzón MJ, Genescà M] Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Ayinampudi V] InterAx Biotech AG, PARK InnovAARE, 5234 Villigen, Switzerland |
dc.identifier.pmid | 34948390 |
dc.identifier.wos | 000737887800001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |